Drugs that contain Safinamide Mesylate

1. Drug name - XADAGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8278485 MDD US Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Jun, 2027

(4 years from now)

US8076515 MDD US Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Dec, 2028

(6 years from now)

CN103284984A MDD US Process For The Production Of 2- [4 - ( 3- And 2-Flu0R0Benzyl0Xy) Benzylamin0] Propan Amides
Jun, 2027

(4 years from now)

CN101472880B MDD US Process For The Production Of 2-[4-(3-And 2) Benzylamino] Propionamide.
Jun, 2027

(4 years from now)

CN101472880A MDD US Process For The Production Of 2-[4-(3- And 2-Fluorobenzyloxy)Benzylamino]Propanamides
Jun, 2027

(4 years from now)

CN103284984B MDD US Method For The Production Of 2 - [3 - (4-And 2) Benzylamino] Propionamide
Jun, 2027

(4 years from now)

IN200900339P4 MDD US Process For The Production Of 2-[4-(3- And 2-Fluorobenzyloxy)Benzylamino]Propanamides
Jun, 2027

(4 years from now)

IN276509B MDD US Process For The Production Of 2-[4-(3- And 2-Fluorobenzyloxy)Benzylamino]Propanamides
Jun, 2027

(4 years from now)

EP2029524B1 MDD US Process For The Production Of 2- [4 - ( 3- And 2-Fluorobenzyloxy) Benzylamino] Propan Amides
Jun, 2027

(4 years from now)

EP2474521A1 MDD US High Purity Degree 2-[4-(3- And 2-Fluorobenzyloxy)Benzylamino]Propanamides For Use As Medicaments And Pharmaceutical Formulations Containing Them
Jun, 2027

(4 years from now)

EP2029524A1 MDD US Process For The Production Of 2- [4 - ( 3- And 2-Fluorobenzyloxy) Benzylamino] Propan Amides
Jun, 2027

(4 years from now)

EP2474521B1 MDD US High Purity Degree 2-[4-(3- And 2-Fluorobenzyloxy)Benzylamino]Propanamides For Use As Medicaments And Pharmaceutical Formulations Containing Them
Jun, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283380 MDD US Methods for treatment of parkinson's disease Mar, 2031

(8 years from now)

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.